Maine providers face a continuous stream of payer policy changes: coverage edits, prior authorization expansions, billing code revisions, and Medicaid reimbursement updates that affect day-to-day practice operations. This page surfaces every tracked policy change that explicitly names Maine, so your billing and compliance teams can act before the effective date, not after a claim denial.
Point32Health/Harvard Pilgrim Health Care is adding new CPT codes to four laboratory testing policies effective December 1, 2026. Billing teams must update their systems to recognize and process these newly covered codes: 0421U for colorectal cancer screening, 82950 for diabetes testing, 87638 for microorganism identification, and 87627, 0600U, 0601U, and 0610U for pathogen panel testing.
Effective December 1, 2026, Anthem Medicare Advantage is implementing a new combined reimbursement policy (G-20001) that prohibits reimbursement for laboratory services billed with modifier 90 (pass-through billing). Providers must bill directly for laboratory services and will be reimbursed at 100% of the applicable fee schedule. The existing modifier 91 guidance for repeat clinical diagnostic laboratory tests remains unchanged and is consolidated into this new policy. The prior modifier 91 policy (G-06020) is being retired.
This is a comprehensive Medicare Advantage coverage policy for molecular biomarker tests used in prostate cancer risk stratification (effective 10/1/2026). The policy establishes coverage criteria for tests like ArteraAI, EpiSwitch, IsoPSA, MyProstateScore 2.0, ProMark, and ProsTAV, with coverage determinations based on MAC-specific LCDs/LCAs that vary by geographic jurisdiction. Billing teams must identify the correct MAC jurisdiction and apply the corresponding LCD requirements for each test ordered.
This is a comprehensive Medicare Advantage bariatric surgery coverage policy (HUM-1020-005) effective October 1, 2026, that outlines coverage determinations, limitations, and coding requirements for various bariatric procedures. The policy applies Humana's Medicare Advantage coverage standards and references applicable MAC Local Coverage Determinations by geographic jurisdiction, with specific rules varying by state and MAC region.
Effective September 1, 2026, Harvard Pilgrim Health Care Commercial (and Point32Health products as of July 1, 2026) will deny all related ancillary and supporting services when a primary service is denied due to lack of prior authorization, untimely authorization, or failure to meet medical necessity criteria. This includes medications supporting the denied procedure, whether billed on the same claim or separately. Specific exceptions apply to radiology professional components, anesthesia, ambulance, pathology professional-only services, and pre/post services outside the date of service.
This is a revised Medicare Advantage medical coverage policy for spinal fusion surgery (effective 09/01/2026) that consolidates coverage determination, limitations, coding information, and evidence summaries for cervical, lumbar, and thoracic spinal fusion procedures. The policy references multiple MAC-specific Local Coverage Determinations (LCDs) across geographic jurisdictions and outlines covered procedures including traditional fusion, minimally invasive approaches (DLIF, XLIF, MITLIF), sacroiliac joint fusion, and interlaminar fusion techniques. Billing teams must align claims submission with the applicable MAC LCD based on patient location and ensure procedures meet specific medical necessity criteria outlined in the referenced determinations.
This is a comprehensive Medicare Advantage coverage policy for Benign Prostatic Hyperplasia treatments effective September 1, 2026. The policy outlines coverage determinations for multiple BPH treatment modalities including surgical procedures (TURP, prostatectomy, laser therapies), temporary implanted devices, stents, and diagnostic testing. The policy references multiple MAC-specific Local Coverage Determinations (LCDs) that vary by geographic jurisdiction, requiring billing teams to verify applicable coverage rules based on patient location.
Effective September 1, 2026, Synapse Health will manage DME ordering and fulfillment for select UnitedHealthcare Medicare Advantage plans in multiple states. Providers must transition to prescribing through the Synapse Health e-prescribing portal, and DME suppliers must join the Synapse Health network to continue serving UnitedHealthcare members. This change affects Individual HMO/PPO plans, C-SNP, and D-SNP plans in 11 states, with a defined list of covered and non-covered DME categories.
This is a comprehensive Medicare Advantage coverage policy for neuroablative techniques used to treat chronic pain, effective 08/06/2026. The policy defines coverage criteria, eligible procedures (including radiofrequency ablation, cryoablation, chemical neurolysis, and specialized devices like Intracept), and references MAC-specific LCDs and billing codes by geographic jurisdiction. Billing teams must verify applicable MAC guidelines for their state and ensure claims comply with local coverage determinations.
This is a comprehensive Medicare Advantage policy on neuroablative techniques for chronic pain management, effective 08/06/2026. The policy defines covered denervation procedures (radiofrequency ablation, cryoablation, facet denervation, basivertebral nerve ablation, and others) and references MAC-specific LCDs and NCDs that vary by geographic jurisdiction. Billing teams must verify applicable MAC requirements for their region before processing claims for these procedures.
Humana Medicare Advantage updated its Percutaneous Coronary Intervention (PCI) coverage policy effective August 3, 2026, clarifying medical necessity criteria for PCI procedures and adding specific coverage requirements for Coronary Intravascular Lithotripsy (IVL) when treating severely calcified coronary stenosis. The policy applies MAC-specific LCDs across multiple jurisdictions and establishes that PCI is covered for acute coronary syndrome, chest pain despite optimal medical therapy, in-stent restenosis, recent STEMI, and silent ischemia.
This is a comprehensive Medicare Advantage policy on genetic testing for hereditary cancer syndromes, effective August 3, 2026. The policy establishes coverage guidelines for germline genetic testing across multiple cancer types (melanoma, gastric cancer, neuroendocrine tumors, renal cell carcinoma, and others) and references specific MAC-based Local Coverage Determinations (LCDs) that vary by geographic jurisdiction. Billing teams must verify applicable MAC jurisdiction and LCD requirements before processing claims.
Humana Medicare Advantage has updated its cardiac catheterization and coronary angiography coverage policy (Policy HUM-1034-008), effective 08/03/2026. The policy establishes specific medical necessity criteria for coronary/bypass angiography procedures, requiring documented moderate to severe ischemia confirmed by nuclear imaging, echocardiography, cardiac MRI, or exercise testing. Billing teams must verify these criteria are met and documented before submitting claims to avoid denials.
This is a comprehensive Medicare Advantage policy for Benign Prostatic Hyperplasia (BPH) treatments that became effective on August 3, 2026. The policy outlines coverage for multiple surgical and minimally invasive treatment modalities including TURP, laser therapies, temporary implanted devices, and stents, with specific coverage determinations varying by MAC jurisdiction. Billing teams must verify applicable MAC-specific LCDs and NCDs by geographic location before processing BPH treatment claims.
Point32Health has implemented a cascading denial policy: when a primary service is denied for lack of prior authorization, untimely authorization, or failure to meet medical necessity criteria, ALL related ancillary services, supporting services, procedures, and medications billed on the same or separate claims will also be denied. This policy is effective immediately for most Point32Health products (July 1, 2026) and will take effect September 1, 2026 for Harvard Pilgrim Health Care Commercial, with specific exceptions for radiology professional components, anesthesia, ambulance, pathology professional components, and pre/post services outside the date of service.
Point32Health is implementing a cascading denial policy effective July 1, 2026 (September 1, 2026 for Harvard Pilgrim Commercial) where any ancillary or supporting services related to a denied prior authorization claim will also be denied, including medications and procedures billed separately. Ambulance services and radiology/lab report readings are excluded, and Maine providers are exempt from this policy.
This is a revised Medicare Advantage policy for breast imaging (effective 07/01/2026) that establishes coverage criteria for mammography, digital breast tomosynthesis, breast MRI, and ultrasound. The policy clarifies medical necessity requirements and references applicable Local Coverage Determinations (LCDs) by MAC jurisdiction. Billing teams must verify which MAC jurisdiction applies to their geographic location to determine specific coverage rules.
Effective January 1, 2026, Harvard Pilgrim Health Care Commercial and Tufts Health Direct plans are significantly restricting coverage of weight loss medications, including GLP-1 drugs for weight loss and alternative indications (cardiovascular, comorbidities). Most formularies (Core, Select, ConnectorCare) will exclude coverage entirely, while plans retaining coverage must require new GLP-1 users to complete a 6-month behavior modification program before accessing Zepbound. All existing prior authorizations for weight loss medications will terminate with no grandfathering.
Harvard Pilgrim Health Care and Tufts Health Direct will exclude coverage of weight loss medications including GLP-1 drugs for weight loss and alternative indications (cardiovascular conditions) starting January 1, 2026. Plans that retain coverage will require a 6-month behavior modification program for new GLP-1 prescriptions, with Zepbound as the preferred medication.
Harvard Pilgrim and Tufts Health Direct will significantly restrict weight loss medication coverage starting January 1, 2026. Most formularies will exclude all weight loss drugs including GLP-1s, while remaining coverage will require a 6-month behavior modification program for new patients. Existing authorizations will be terminated without grandfathering.
Harvard Pilgrim and Tufts Health Direct are significantly restricting weight loss medication coverage effective January 1, 2026. Most formularies will exclude all weight loss drugs including GLP-1 medications, with new prior authorization requirements and a mandatory 6-month behavior modification program for remaining covered plans.
Harvard Pilgrim Health Care is implementing a comprehensive laboratory benefit management program with new payment policies and automated claims edits for Commercial products. The program affects 56 specific lab test categories across office, hospital outpatient, and independent laboratory settings, with different effective dates for Maine providers (Dec 1, 2025) versus other service areas (Nov 1, 2025).
Aetna is implementing multiple prior authorization changes for specialty drugs and procedures, removing precertification requirements for artificial insemination procedures, and requiring valid CPT/HCPCS codes for behavioral health services. Key changes take effect at various dates from November 2025 through February 2026.
Point32Health has updated multiple Medical Necessity Guidelines affecting prior authorization requirements and coverage for TMJ procedures, sleep management devices, neurostimulators, basivertebral nerve ablation, and investigational services across Harvard Pilgrim Commercial and Tufts Health plans. Key changes include new prior auth requirements for TMJ condylectomy and meniscectomy (effective 1/1/2027), retirement of sleep-related MNGs with removal of prior auth for specific HCPCS codes (effective 12/1/2026), updates to neurostimulator and sacral nerve stimulation criteria (effective 10/1/2026), and changes to coverage for genetic testing and nerve allografts.
Point32Health is requiring all contracted ABA (applied behavioral analysis) providers to obtain accreditation from a nationally recognized accrediting body. This requirement applies to Harvard Pilgrim and Tufts Health Plan products across all states in their service area, with staggered deadlines: Massachusetts and Rhode Island providers must be accredited by January 1, 2027, and all other providers by January 1, 2028. Billing and authorization processes remain unchanged.
UnitedHealthcare is reminding providers that multigene RNA panel testing for hereditary cancer is considered unproven and will be denied. Only DNA-only hereditary cancer panels and single-gene RNA testing remain covered under applicable medical policy and prior authorization requirements.
Point32Health (Harvard Pilgrim and Tufts Health Plan) has changed ABA therapy prior authorization requirements - providers must now use practice NPI (Type 2) instead of individual therapist NPI when submitting authorization requests. Additionally, accreditation deadlines have been extended for center-based ABA providers in New Hampshire, Maine, and Vermont to January 1, 2028.
Humana Medicare Advantage revised its neuroablative techniques for chronic pain policy effective 11/01/2026. The policy update describes coverage criteria, limitations, and coding guidance for multiple denervation procedures (radiofrequency ablation, cryotherapy, facet denervation, basivertebral nerve ablation, and other neuroablative techniques). The practice must verify applicable MAC LCDs by geographic jurisdiction, obtain prior authorization as required, and ensure claims are submitted with correct coding and documentation.
Point32Health has released comprehensive payment policy updates affecting 13 service categories across Harvard Pilgrim and Tufts Health plans, effective October 1, 2026 and December 1, 2026. Most updates are administrative clarifications, but the Obstetrics/Gynecology policy includes substantive new maternity billing guidelines and coding changes effective January 1, 2027. The Radiology and Diagnostic Imaging policy consolidates and replaces two separate legacy policies.
Humana Medicare Advantage has updated its Psychiatric Inpatient Hospitalization policy (HUM-9000-004) effective September 1, 2026. The policy reinforces the two-midnight benchmark for admission coverage and clarifies that psychiatric inpatient care must meet medical necessity standards based on complex medical factors. Billing teams must ensure claims documentation supports the two-midnight requirement and align with applicable MAC Local Coverage Determinations by geographic jurisdiction.
Humana Medicare Advantage has updated its policy on molecular diagnostic assays and breath testing for transplant rejection, effective 08/30/2026. This policy establishes coverage criteria and references for gene expression profiling tests, antigen-specific T-cell function assays, breath testing (BMAC/Heartsbreath), and donor-derived cell-free DNA tests used to monitor organ transplant recipients. Billing teams must verify MAC-specific Local Coverage Determinations (LCDs) by geographic jurisdiction, as coverage and coding requirements vary significantly by region.
Humana Medicare Advantage has updated its Liquid Biopsy coverage policy (Policy HUM-1151-014), effective 08/03/2026. This policy establishes coverage criteria for liquid biopsy tests (blood-based biomarker analysis for cancer detection and treatment monitoring) across multiple jurisdictions under Medicare Administrative Contractors. The policy requires medical necessity documentation and adherence to MAC-specific Local Coverage Determinations, with coverage determined through analytical/clinical validity standards and DEX Registry evaluation where CMS guidance is absent.
Anthem Blue Cross and Blue Shield is reminding providers in 12 states (including New York) that the Bundled Services and Supplies — Facility reimbursement policy applies to both inpatient and outpatient facility fees effective July 1, 2026. Providers are prohibited from balance-billing members based on this policy, and must review specific policy details on the provider website to ensure proper billing compliance.
Anthem Blue Cross and Blue Shield is reminding providers that the Bundled Services and Supplies — Facility reimbursement policy applies to both inpatient and outpatient facility fees effective July 1, 2026. Providers are prohibited from balance-billing members under this policy, and billing teams must ensure compliance with bundled service requirements to avoid claim denials and member disputes.
This is a Medicare Advantage policy revision (effective 07/01/2026) for Coronary CT Angiography, Fractional Flow Reserve with CT, and adjunctive cardiac testing. The policy establishes that Humana follows applicable Local Coverage Determinations (LCDs) by MAC jurisdiction for CCTA (CPT 75574) and FFRCT (CPT 75580), with specific LCD guidance for each geographic region. Billing teams must ensure prior authorization and medical necessity documentation align with the applicable LCD in the patient's service area.
Harvard Pilgrim Health Care will cover specialized risk screening tests for Maine first responders starting July 1, 2026. Coverage includes cancer screening, blood tests, mammography, colonoscopy, prostate exams, cardiovascular inflammation tests, and nutritional assessments when deemed medically appropriate by treating providers.
This is an informational newsletter (OfficeLink Updates - March 2026) containing multiple policy updates and operational guidance for Aetna providers. Key items include: (1) new claim edits effective June 1, 2026 as part of the Claim and Code Review Program (CCRP); (2) an update to the treatment room services policy (originally effective April 1, 2021); and (3) reminders about prior authorization submission procedures, provider profile maintenance, and behavioral health resources. The newsletter applies to Commercial and Medicare lines of business unless otherwise specified.
Humana Medicare Advantage has updated coverage criteria for cardiac catheterization and coronary angiography procedures (CPT 93454-93461), specifying detailed requirements for moderate to severe ischemia documentation and stress test results. The policy establishes specific thresholds for nuclear perfusion, echocardiogram, and other diagnostic tests that must be met for coverage approval.
Humana Medicare Advantage has updated their policy for proton beam, neutron beam, and carbon ion radiation therapy, establishing specific medical necessity criteria for proton beam therapy, limiting neutron beam therapy to inoperable salivary gland tumors, and excluding carbon ion therapy entirely. The policy also covers prostate rectal spacers with specific criteria.
Humana has revised their Medicare Advantage policy for advanced imaging of the head and neck, establishing specific medical necessity criteria for MRA and MRI procedures. The policy provides jurisdiction-specific coverage determinations and clarifies when high-risk intracranial aneurysmal screening MRA is considered medically necessary.
Updated Medicare Advantage coverage policy for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) with refined criteria for prostate rectal spacers, including specific medical necessity requirements and exclusions for patients with posterior extraprostatic extension or rectal wall invasion.
Humana has released a new Medicare Advantage medical coverage policy for psychological and neuropsychological testing, establishing coverage criteria and billing guidelines for related CPT codes. This policy references multiple Medicare Administrative Contractor (MAC) Local Coverage Determinations across different states to determine medical necessity requirements.
AARP Medicare Supplement plans from UnitedHealthcare will automatically offset overpayments from future ACH electronic payments instead of sending letters requesting refunds. This streamlined process applies to providers receiving electronic payments through Optum Pay in 33 specified states.
Point32Health is implementing comprehensive changes to Applied Behavioral Analysis (ABA) therapy policies effective January 1, 2026, including expanded Down syndrome coverage in Massachusetts, new InterQual criteria for prior authorizations, and coding changes that eliminate HCPCS codes H0031/H0032 for Harvard Pilgrim Commercial plans while requiring prior auth for CPT 0362T on Tufts Health Direct.
Point32Health is implementing a new Select formulary for Harvard Pilgrim Health Care large group products starting January 1, 2026, which excludes all weight loss medication coverage and is designed for cost containment. This affects large group commercial plans in MA, NH, ME, and RI, with members being notified before their coverage changes.
Point32Health will launch new Harvard Pilgrim Health Care Commercial products called National Access EPO (in MA, NH, RI) and National Access (in ME) starting January 1, 2026. These EPO-style plans don't require PCPs or referrals, offer five-state coverage plus UnitedHealthcare's Choice Plus network nationally, but have no out-of-network benefits.
Aetna's June 2025 newsletter announces multiple policy updates effective September 1, 2025 (new claim edits for CCRP), October 1, 2025 (commercial drug list changes), and ongoing pharmacy/Medicare updates. Key changes include new claim edits in the Claim and Code Review Program (CCRP), commercial drug list modifications requiring prior authorization requests, and behavioral health clinical criteria updates. Billing teams must monitor Availity for new edits, update prior authorization workflows for pharmacy changes, and ensure provider directory information is current.
Effective August 1, 2025, Aetna will no longer cover surgical pathology code 88305 when billed with prostate procedures 55700/55706 on the same date, and will limit G0416 to once per date of service. Additionally, effective July 1, 2025, certain specialty medications will move between medical and pharmacy benefits for fully insured commercial members.
State insurance and HMO regulations apply to Commercial, Medicare and Medicaid products and health plans sold in each state, and the federal Medicare participation rules apply to all Medicare and Medicare/Medicaid dual eligible products. Examples of state timelines include 60 calendar days to conclude credentialing in Arizona, 60 calendar days for physicians in Colorado, and no more than 90 days for initial credentialing in New Jersey after receipt of a complete application. Maryland and North Carolina restrict requests for information beyond the uniform credentialing form, and federal rules require the information verified for a credentialing decision to be no more than 180 calendar days old at the time of the Credentialing Committee decision. California rules take effect January 1, 2027 for 90-day determinations and January 1, 2028 for use of the CAQH credentialing form.
UnitedHealthcare published new guidance for Maine providers highlighting covered alternatives to opioid medications, including non-opioid pain medications, physical therapy, acupuncture, and other non-medication pain management options. This applies to UnitedHealthcare commercial and Individual Exchange plan members in Maine.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.